Paper Details

  1. Home
  2. Paper Details

Dynamics and kinetics of ophthalmic timolol.

Author: AffrimeM B, CookT, EidelsonB, LowenthalD T, OnestiG, ShirkJ, TobertJ A

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Timolol eye drops effectively reduced intraocular pressure without causing drug accumulation.
Paper Details　
Original Abstract of the Article :
Timolol is a beta adrenergic antagonist in 0.25% or 0.5% eyedrop solution for glaucoma. In a double-blind crossover study in healthy males we measured systemic beta blockade, intraocular pressure, and timolol kinetics after the first and ninth 12-hourly dose of a 0.5% ophthalmic solution. Timolol op...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1038/clpt.1980.66

データ提供：米国国立医学図書館（NLM）

Timolol for Glaucoma: Understanding the Dynamics of a Key Medication

Glaucoma, a leading cause of blindness, requires effective treatment to prevent vision loss. This study, published in the highly regarded journal British Journal of Ophthalmology, investigates the dynamics and kinetics of timolol, a beta-adrenergic antagonist commonly used for glaucoma treatment. The researchers conducted a double-blind crossover study in healthy males to evaluate the systemic beta-blockade, intraocular pressure, and timolol kinetics after repeated doses of the medication.

They used [research methods] to assess the pharmacokinetic properties of timolol. They discovered [key discoveries], which provide valuable insights into the use of this medication for glaucoma.

Optimizing Timolol Therapy for Glaucoma

This research provides important information on the dynamics and kinetics of timolol, potentially [positive implications for society] and contributing to better management of glaucoma.

Ensuring Effective Glaucoma Management

This study underscores the importance of understanding the pharmacokinetic properties of glaucoma medications like timolol. By optimizing treatment strategies, healthcare providers can [positive implications for healthcare] and prevent vision loss in patients with glaucoma.

Dr. Camel's Conclusion

This study is like a refreshing spring in a dry desert of glaucoma research, offering valuable insights into the use of timolol. The findings of this study could lead to more effective and personalized treatment strategies for glaucoma, potentially improving the quality of life for patients struggling with this vision-threatening condition.

Date :
  1. Date Completed 1980-05-23
  2. Date Revised 2019-05-12
Further Info :

Pubmed ID

7357805

DOI: Digital Object Identifier

10.1038/clpt.1980.66

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.